



For further information please contact:

Media enquiries

Northbank Communications

Rebecca Todd, Senior Account Manager

Tel: +44 (0)20 7886 8157

Mobile: +44 (0)7801 573073

E-mail: r.todd@northbankcommunications.com

Sue Charles, CEO

Tel: +44 (0)20 7886 8152

Mobile: +44 (0)7968 726585

E-mail: s.charles@northbankcommunications.com

At Oxford Genome Sciences (UK) Ltd

Christian Rohlf, Chief Executive Officer

Tel: +44 (0) 1235 861770

E-mail: christian.rohlf@oxfordgenomesciences.com

<http://www.OxfordGenomeSciences.com>

Oxford Genome Sciences appoints Jeff Warren to the Board of Directors

Oxford, UK, 7 June 2005 - Oxford Genome Sciences (UK) Ltd (OGeS) today announced the appointment of Jeff Warren as its first non-executive director. Mr Warren brings nearly 30 years financial management experience, including high level corporate governance and regulatory environment experience, having served as a Finance Director and CEO in the UK Financial Services industry.

"We are very pleased to welcome Jeff to the Board of OGeS. A qualified and highly experienced accountant, he has a strong history and track record of success in the financial services industry, which will be extremely useful to OGeS as it grows to assert its position as a leading player in the proteomics and protein biomarker sector. I recognise the importance of a strong Board and sound corporate governance, and Jeff will be a strong addition to our team", said Dr Christian Rohlf, CEO of OGeS.

Jeff Warren was CFO of Bristol and West Building Society from 1992. Following the acquisition of Bristol and West by Bank of Ireland, he was appointed CEO of Bristol and West PLC in 1999, and subsequently also given responsibility for the Bank of Ireland UK Branch network. In 2003 he moved to take on a role at Group level in Dublin, as Group Chief Development Officer, reporting to the Bank of Ireland CEO. In 2004 he returned to the UK to develop a career as a non-executive director.

"I am excited by the potential for OGeS to develop a leading position as a specialist in the proteomics and biomarker sectors. OGeS has a strong team, excellent technology and intellectual property, and the support of quality investors. It has an exciting future and I look forward to making my contribution", commented Jeff Warren.

- ENDS -



About Oxford Genome Sciences

Oxford Genome Sciences (OGeS) is applying proteomics technologies to the discovery and development of novel therapeutic and diagnostic products. Through the integration of proteomics and genomics the Company believes that a new frontier is being opened in the development of therapeutic and diagnostic products. It has established a substantial resource for applying novel concepts in proteomics technologies for biomarker discovery and evaluation. Its platforms for the systematic high-throughput characterisation of proteins expressed in clinical samples create new opportunities for improving the time and cost efficiency of drug development, as well as early disease detection, prognosis and monitoring. OGeS owns Oxford Genome Anatomy Project (OGAP™), the world's largest proteomics database to date, comprising over one million peptide sequences from ~50 different tissues involved in ~60 different diseases. The Company provides proteomics analysis services to pharmaceutical companies that complement its in-house proteomics efforts, as part of the drug discovery and development process. OGeS is pursuing wide-ranging business development activities to maximise the value of its expertise in proteomics.

The Company is located near Oxford in the UK and began trading 18 months ago after senior members of the Proteomics division at Oxford GlycoSciences plc (OGS) acquired technology, infrastructure, intellectual property, bioinformatics and data from Oxford GlycoSciences and Confirmant following its acquisition by Celltech plc.

For further information, please see www.oxfordgenomesciences.com